NXTS

Nexentis Technologies Inc

• TipRanks·05/18 13:36

  Nexentis Technologies says MitoCareX Bio achieves drug discovery milestone

• Benzinga·05/18 13:33

  Nexentis Subsidiary MitoCareX Hits First Drug‑Discovery Milestone With Optimized Molecule

• PUBT·05/18 13:30

  Nexentis unit MitoCareX Bio generates optimized hit molecule for cancer, inflammation program

• Reuters·05/18 13:30

  NEXENTIS ANNOUNCES MITOCAREX BIO ACHIEVES KEY R&D MILESTONE, GENERATING A SUBSTANTIALLY IMPROVED HIT MOLECULE ON THE PATH TO PRE-CLINICAL DEVELOPMENT

• PUBT·05/13 11:13

  Nexentis unit MitoCareX Bio generates optimized hit molecule in MITOLINE drug program

• TipRanks·05/08 14:05

  Nexentis Technologies Inc trading halted, volatility trading pause

• TipRanks·05/08 13:54

  Nexentis Technologies Inc trading resumes

• TipRanks·05/05 13:20

  Nexentis Technologies announces Mitoline U.S. trademark registration approval

• Benzinga·05/05 11:49

  Nexentis Technologies' Subsidiary Receives U.S. Patent And Trademark Office Official Trademark Registration For Its MITOLINE Algorithm Platform

• PUBT·05/05 11:34

  Nexentis wins USPTO trademark registration for MitoCareX MITOLINE platform

• TipRanks·04/30 22:08

  Nexentis Shareholders Approve Reverse Split and Financing Flexibility

• PUBT·04/30 21:22

  Nexentis Technologies holds special shareholder meeting; reverse split amendment approved

• Reuters·04/16 20:48

  BRIEF-Nexentis Technologies Inc - May Offer Up To $100 Million Of Securities - SEC Filing

• TipRanks·04/16 20:21

  Nexentis Technologies files $100M mixed securities shelf

• TipRanks·04/06 13:01

  Nexentis Technologies Announces 1-for-7 Reverse Stock Split